Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies Inc (ALUR) delivers innovative weight management solutions through its swallowable gastric balloon and integrated digital platform. This page provides authorized updates on corporate developments, clinical advancements, and strategic initiatives shaping the future of non-invasive obesity treatment.
Investors and healthcare professionals will find timely announcements including quarterly earnings reports, FDA regulatory updates, partnerships with medical institutions, and new clinical study findings. Our curated news collection ensures transparent access to material events affecting the company's position in the medical device sector.
Key content categories include product innovation timelines, peer-reviewed research publications, executive leadership changes, and global expansion updates. Each announcement is sourced directly from official corporate communications to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Allurion's latest developments in AI-powered patient monitoring systems and procedure-less weight loss technologies. Regularly updated to reflect the company's progress in merging medical devices with digital health solutions.
Allurion Technologies (NYSE: ALUR) has announced a registered direct offering of 1,240,000 shares of common stock priced at $6.00 per share, aiming to raise approximately $7.4 million in gross proceeds. The offering is priced at-the-market under NYSE rules.
In a concurrent private placement, the company will issue warrants to purchase up to 1,240,000 additional shares at an exercise price of $6.00 per share. These warrants will become exercisable immediately following stockholder approval and will expire five years after such approval. The company also agreed to reprice its outstanding warrants from July 2024 to $6.00 per share for existing warrant holders participating in this offering.
Roth Capital Partners is serving as the exclusive placement agent. The offering is expected to close around January 27, 2025. The proceeds will be used for working capital and general corporate purposes.
Allurion Technologies (NYSE: ALUR) has announced plans to start a clinical study combining its Allurion Program with GLP-1 agonists to optimize muscle mass during weight loss treatment. The initiative addresses a significant concern with GLP-1 therapy, which has shown approximately 40% reduction in lean mass as a proportion of total weight lost.
Previous studies of the Allurion Balloon combined with their Virtual Care Suite have demonstrated promising results: In a study of 571 patients, participants gained 5.6% in lean body mass while losing 14% of total body weight over four months. Another study with 167 patients showed a 15.7% weight reduction with no muscle mass loss.
The company aims to prove that combining their balloon technology with GLP-1 therapy could become the gold standard for obesity care by enabling significant weight loss while improving muscle mass and body composition.
Allurion Technologies (NYSE: ALUR) announced the issuance of a new U.S. patent for their next-generation weight loss device. The U.S. Patent No. 12,209,677, titled “Binary Fluid Control Valve System,” was issued on January 15, 2025. This patent covers enhanced claims for Allurion's proprietary Balloon technology, specifically focusing on the precision of its valve system. The patent provides protection through July 2039. This addition brings Allurion's patent portfolio to 20 U.S. patents and 59 global patents.
The Allurion Program combines the Allurion Gastric Balloon, a swallowable and procedure-less gastric balloon, with the Allurion Virtual Care Suite, including a mobile app, connected scale, and Allurion Insights for healthcare providers. Patients using the Allurion Program typically lose 10-15% of their total body weight and can increase muscle mass in some cases.
Shantanu Gaur, Allurion’s Founder and CEO, emphasized that the new patent strengthens their global patent portfolio, reflecting the innovation and effectiveness of their weight loss solutions.
Allurion Technologies (NYSE: ALUR) has announced a private placement agreement with RTW Investments for 841,751 shares at $2.97 per share, expected to generate $2.5 million in gross proceeds. The agreement includes an option for up to $10 million in additional funding tranches and is set to close around January 15, 2025.
The company also released preliminary Q4 2024 results, with expected revenue of approximately $5.6 million for the quarter and $32 million for the full year 2024, meeting previous guidance. Procedure volume growth for the year, excluding France, is estimated at 4%, exceeding earlier projections.
The funding is expected to extend the company's runway through early 2026, supporting their 2025 plans including scaling commercial strategy, advancing FDA approval process for the Allurion Balloon, working toward profitable operations in 2026, expanding digital business lines, and resuming French market operations.
Allurion Technologies (NYSE: ALUR) announced positive topline results from its AUDACITY trial, evaluating the safety and efficacy of the Allurion Balloon. This pivotal FDA trial is the first to report primary outcomes beyond 9 months for an intragastric balloon for weight loss. The trial included 550 subjects randomized 1:1 to either two cycles of the Allurion Balloon or a control group receiving moderate intensity lifestyle therapy.
At 48 weeks, over 50% of Allurion Balloon subjects lost more than 5% of their total body weight (58%; p-value = 0.0089). The Allurion Balloon group exhibited a 3.77% mean difference in total body weight loss compared to the control group, with a 2.69% superiority margin, which was under the pre-specified 3% margin (p-value=0.1616). At 40 weeks, the mean difference was 4.22%, exceeding the 3% margin.
The trial reported a low 3.1% rate of serious adverse events, the lowest for a liquid-filled intragastric balloon in an FDA trial. The fourth and final module of the Pre-Market Approval application is planned for 2025.
Allurion Technologies (NYSE: ALUR) announced a 1-for-25 reverse stock split effective January 3, 2025. The split will reduce outstanding shares from approximately 67.8 million to 2.7 million, with no fractional shares issued. Trading on NYSE will begin on a split-adjusted basis on January 3, 2025.
The decision follows NYSE's notification on August 12, 2024, regarding non-compliance with the minimum $1.00 per share requirement. Proportional adjustments will be made to equity incentive plans, convertible notes, and warrants. Post-split, public warrants (ALUR WS) will be exercisable for 0.056818 shares at $202.50 per share.
Allurion Technologies (NYSE: ALUR) announced that the NYSE has accepted its plan to regain compliance with the exchange's Minimum Market Capitalization Standard. The company, focused on ending obesity, has until March 1, 2026 to meet the listing requirements outlined in Section 802.01B of the NYSE's Listed Company Manual. Dr. Shantanu Gaur, Founder and CEO, expressed satisfaction with this development and emphasized their commitment to increasing shareholder value.
Allurion Technologies (NYSE: ALUR) has launched AllurionMeds, combining compounded GLP-1 medications with an AI-powered platform featuring Coach Iris for weight management. The program includes virtual dietician access and a smart scale measuring weight, muscle, and bone mass. The initiative addresses key GLP-1 challenges: medication adherence, muscle mass loss, and high costs. The program utilizes FDA-registered pharmacies for drug sourcing and expands Allurion's presence to all 50 US states. This launch targets a projected $100 billion GLP-1 market expected to reach 30 million users by 2030.
Allurion Technologies (NYSE: ALUR) reported Q3 2024 financial results with revenue of $5.4 million, down from $18.2 million in Q3 2023. The decline was attributed to destocking, macroeconomic headwinds, and suspended sales in France. The company's AI Virtual Care Suite revenue grew 82% year-over-year. Gross profit margin decreased to 58% from 77% in Q3 2023. The company updated its full-year 2024 revenue guidance to $30-35 million and announced a restructuring plan targeting 50% reduction in operating expenses, aiming for profitability by end of 2025.
Allurion Technologies (NYSE: ALUR) presented significant data at Obesity Week 2024, showcasing results from their largest real-world study involving 19,428 patients across 72 countries. The study demonstrated an average weight reduction of 12.2% after four months using the Allurion Program. Additionally, a second study revealed that patients who previously had unsuccessful results with liraglutide achieved an average 17.6% weight reduction after four months on the Allurion Program. This group included patients where 55% had no weight loss and 45% had less than 5% weight loss with GLP-1 medications.
